


Application No.: 09/687,951

REMARKS

The amendment to claim 29 is supported by the specification, page 11, line 10. New claim 35 is supported by claim 29. Claims 17 and 20-35 are now pending. No new matter has been added.

Attached herewith is a marked-up version of the changes made to the claims by this amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,


Jonathan P. Taylor, Ph.D.
Registration No. 48,338
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200

VERSION WITH MARKINGS TO SHOW CHANGES MADE

29. (Amended) The injectable formulation of claim 28, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), an anti-vascular endothelial growth factor Fab (anti-VEGF Fab), a [glucagons] glucagon-like peptide I (GLP-I), a nerve growth factor, [and] an insulin-like growth factor, and an antibody.